HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Byung-Nak Ahn Selected Research

(3- (4- (2(4- (4chloro- phenyl)- 3,6- dihydro- 2H- pyridin- 1- yl)- ethoxy)- phenyl)- (2S)- ethoxy- propionic acid)

10/2008PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Byung-Nak Ahn Research Topics

Disease

1Hepatocellular Carcinoma (Hepatoma)
10/2008
1Insulin Resistance
10/2008

Drug/Important Bio-Agent (IBA)

1(3- (4- (2(4- (4chloro- phenyl)- 3,6- dihydro- 2H- pyridin- 1- yl)- ethoxy)- phenyl)- (2S)- ethoxy- propionic acid)IBA
10/2008
1Glucose (Dextrose)FDA LinkGeneric
10/2008
1Insulin (Novolin)FDA Link
10/2008
1LipidsIBA
10/2008
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
10/2008
1PPAR alphaIBA
10/2008